<DOC>
	<DOC>NCT00304447</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of Mylotarg速 infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of Mylotarg速 induced complete response (CR) and complete response with incomplete platelet recovery (CRp) at one-month post treatment.</brief_summary>
	<brief_title>Study Evaluating the Effect of Corticosteroids on Mylotarg速 Infusion-Related Adverse Events in Patients With Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Patients with CD33 positive, resistant or relapsed AML. Patients &gt; 18 years of age. ECOG performance status 02. Fever (&gt;38), chills or hypotension (systolic BP&lt;105mmHg) in the 48 hours preceding therapy. Use of corticosteroids, diphenhydramine or acetaminophen within 24 hours of enrollment. Participation in any other Mylotarg速 protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Mylotarg</keyword>
	<keyword>Safety</keyword>
	<keyword>Adverse Events</keyword>
</DOC>